CO5700789A2 - Composiciones inmunogenicas - Google Patents
Composiciones inmunogenicasInfo
- Publication number
- CO5700789A2 CO5700789A2 CO06034534A CO06034534A CO5700789A2 CO 5700789 A2 CO5700789 A2 CO 5700789A2 CO 06034534 A CO06034534 A CO 06034534A CO 06034534 A CO06034534 A CO 06034534A CO 5700789 A2 CO5700789 A2 CO 5700789A2
- Authority
- CO
- Colombia
- Prior art keywords
- spp
- virus
- antigen
- hepatitis
- immunogenic
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 abstract 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 abstract 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 abstract 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 abstract 1
- 241000588807 Bordetella Species 0.000 abstract 1
- 241000589968 Borrelia Species 0.000 abstract 1
- -1 CASB616 Proteins 0.000 abstract 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241001647372 Chlamydia pneumoniae Species 0.000 abstract 1
- 241000606153 Chlamydia trachomatis Species 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 241000588722 Escherichia Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 241000589989 Helicobacter Species 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000724675 Hepatitis E virus Species 0.000 abstract 1
- 241000709721 Hepatovirus A Species 0.000 abstract 1
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 abstract 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 abstract 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 abstract 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 abstract 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 102100034872 Kallikrein-4 Human genes 0.000 abstract 1
- 241000186781 Listeria Species 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 abstract 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 abstract 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 abstract 1
- 241000588621 Moraxella Species 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 108010008707 Mucin-1 Proteins 0.000 abstract 1
- 241000711386 Mumps virus Species 0.000 abstract 1
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 102000036673 PRAME Human genes 0.000 abstract 1
- 108060006580 PRAME Proteins 0.000 abstract 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 abstract 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 abstract 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 241000702670 Rotavirus Species 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract 1
- 108010002687 Survivin Proteins 0.000 abstract 1
- 108010017842 Telomerase Proteins 0.000 abstract 1
- 241000223996 Toxoplasma Species 0.000 abstract 1
- 102100039094 Tyrosinase Human genes 0.000 abstract 1
- 108060008724 Tyrosinase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 231100000249 enterotoxic Toxicity 0.000 abstract 1
- 230000002242 enterotoxic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108010024383 kallikrein 4 Proteins 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 abstract 1
- 108010079891 prostein Proteins 0.000 abstract 1
- 235000002020 sage Nutrition 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323968.8A GB0323968D0 (en) | 2003-10-13 | 2003-10-13 | Immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700789A2 true CO5700789A2 (es) | 2006-11-30 |
Family
ID=29559207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06034534A CO5700789A2 (es) | 2003-10-13 | 2006-04-07 | Composiciones inmunogenicas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070212328A1 (enExample) |
| EP (1) | EP1684802A2 (enExample) |
| JP (1) | JP2007508273A (enExample) |
| KR (1) | KR20060131749A (enExample) |
| CN (1) | CN1893974A (enExample) |
| AU (1) | AU2004283458A1 (enExample) |
| BR (1) | BRPI0415315A (enExample) |
| CA (1) | CA2541693A1 (enExample) |
| CO (1) | CO5700789A2 (enExample) |
| GB (1) | GB0323968D0 (enExample) |
| IL (1) | IL174542A0 (enExample) |
| IS (1) | IS8387A (enExample) |
| MA (1) | MA28106A1 (enExample) |
| NO (1) | NO20061911L (enExample) |
| RU (1) | RU2006111849A (enExample) |
| WO (1) | WO2005039630A2 (enExample) |
| ZA (1) | ZA200602948B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172476A1 (en) * | 2002-08-12 | 2011-07-28 | Dynavax Tech Corp | Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent |
| EP2261244A3 (en) * | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
| US20100061958A1 (en) * | 2006-09-14 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Modulation of Regulatory T Cells by Human IL-18 |
| SE532249C2 (sv) * | 2006-11-13 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering |
| CA2687632C (en) | 2007-05-24 | 2013-01-15 | Glaxosmithkline Biologicals S.A. | Lyophilised antigen composition |
| WO2009108235A2 (en) * | 2007-12-07 | 2009-09-03 | Tekmira Pharmaceuticals Corporation | Compositions and methods for modulating immune responses to nucleic acids |
| GB0810869D0 (en) * | 2008-06-13 | 2008-07-23 | Isis Innovation | Vaccine adjuvant composition |
| TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| EP2202298A1 (en) | 2008-12-23 | 2010-06-30 | Stichting Dienst Landbouwkundig Onderzoek | Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV |
| EP2381949B1 (en) * | 2008-12-23 | 2012-11-21 | Intervet International BV | Immunostimulating saponins for use in in situ tumor-destruction therapy |
| WO2010147268A1 (ko) * | 2009-06-19 | 2010-12-23 | 아이진 주식회사 | 자궁경부암 백신 |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| CN101814489A (zh) * | 2010-03-02 | 2010-08-25 | 晶科电子（广州）有限公司 | 带有功能芯片的发光二极管封装结构及其封装方法 |
| EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| WO2013082503A1 (en) * | 2011-12-01 | 2013-06-06 | Flow Pharma, Inc. | Peptide particle formulation |
| US20140105970A1 (en) * | 2011-12-01 | 2014-04-17 | Flow Pharma, Inc. | Adjuvant and antigen particle formulation |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| SG11201500243WA (en) * | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| CN116327912A (zh) * | 2021-12-23 | 2023-06-27 | 上海泽润生物科技有限公司 | 带状疱疹疫苗组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0930893B1 (en) * | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| JP2002510644A (ja) * | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
| WO1999056775A1 (en) * | 1998-05-07 | 1999-11-11 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| CN1227030C (zh) * | 1999-04-19 | 2005-11-16 | 史密丝克莱恩比彻姆生物有限公司 | 包含皂甙和免疫刺激寡核苷酸的佐剂组合物 |
| US20010044418A1 (en) * | 2000-03-10 | 2001-11-22 | Shoshana Levy | Treatment of allergies |
-
2003
- 2003-10-13 GB GBGB0323968.8A patent/GB0323968D0/en not_active Ceased
-
2004
- 2004-10-11 CA CA002541693A patent/CA2541693A1/en not_active Abandoned
- 2004-10-11 US US10/575,836 patent/US20070212328A1/en not_active Abandoned
- 2004-10-11 WO PCT/EP2004/011621 patent/WO2005039630A2/en not_active Ceased
- 2004-10-11 AU AU2004283458A patent/AU2004283458A1/en not_active Abandoned
- 2004-10-11 CN CNA2004800372174A patent/CN1893974A/zh active Pending
- 2004-10-11 BR BRPI0415315-4A patent/BRPI0415315A/pt not_active Application Discontinuation
- 2004-10-11 JP JP2006530156A patent/JP2007508273A/ja active Pending
- 2004-10-11 EP EP04790466A patent/EP1684802A2/en not_active Withdrawn
- 2004-10-11 KR KR1020067009353A patent/KR20060131749A/ko not_active Withdrawn
- 2004-10-11 RU RU2006111849/14A patent/RU2006111849A/ru not_active Application Discontinuation
-
2006
- 2006-03-23 IL IL174542A patent/IL174542A0/en unknown
- 2006-03-30 IS IS8387A patent/IS8387A/is unknown
- 2006-04-07 CO CO06034534A patent/CO5700789A2/es not_active Application Discontinuation
- 2006-04-11 ZA ZA200602948A patent/ZA200602948B/xx unknown
- 2006-04-25 MA MA28960A patent/MA28106A1/fr unknown
- 2006-04-28 NO NO20061911A patent/NO20061911L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL174542A0 (en) | 2006-08-01 |
| KR20060131749A (ko) | 2006-12-20 |
| AU2004283458A1 (en) | 2005-05-06 |
| IS8387A (is) | 2006-03-30 |
| JP2007508273A (ja) | 2007-04-05 |
| WO2005039630A2 (en) | 2005-05-06 |
| CA2541693A1 (en) | 2005-05-06 |
| BRPI0415315A (pt) | 2006-12-05 |
| EP1684802A2 (en) | 2006-08-02 |
| CN1893974A (zh) | 2007-01-10 |
| WO2005039630A3 (en) | 2005-07-21 |
| RU2006111849A (ru) | 2007-11-20 |
| MA28106A1 (fr) | 2006-08-01 |
| US20070212328A1 (en) | 2007-09-13 |
| ZA200602948B (en) | 2007-09-26 |
| NO20061911L (no) | 2006-06-07 |
| GB0323968D0 (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700789A2 (es) | Composiciones inmunogenicas | |
| RU2006111847A (ru) | Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему | |
| Lee et al. | Recent advances of vaccine adjuvants for infectious diseases | |
| JP2006512047A5 (enExample) | ||
| Andre et al. | Vaccination greatly reduces disease, disability, death and inequity worldwide | |
| Karch et al. | Vaccine technologies: From whole organisms to rationally designed protein assemblies | |
| CO2018005258A2 (es) | Vacuna del virus herpes simple | |
| JP2007508273A5 (enExample) | ||
| CO5200838A1 (es) | Vacunas | |
| WO2003009812A3 (en) | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | |
| PE20020126A1 (es) | Composicion de vacuna | |
| ES2192582T3 (es) | Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado. | |
| CA2179779A1 (en) | Vaccine compositions comprising oil in water emulsions with tocopherol and squalene | |
| IL174413A0 (en) | Immunological adjuvants compounds | |
| WO2004084936A3 (en) | Modified free-living microbes, vaccine compositions and methods of use thereof | |
| PT2364724E (pt) | Composição de vacina compreendendo um adjuvante de saponina | |
| CA2354046A1 (en) | New cancer treatments | |
| MX9401225A (es) | Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion. | |
| CA2427475A1 (en) | Purification of hbv antigens for use in vaccines | |
| PE97298A1 (es) | Composicion para vacunas | |
| MD20210028A2 (ro) | Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia | |
| EP4324832A3 (en) | Immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases | |
| AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
| Angulo et al. | Trained immunity-based Adjuvated vaccines (TIbAV) approach: β-glucans as example | |
| WO2001070932A3 (en) | Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |